- Home
- RMCO vs ALLR Comparison
RMCO vs ALLR Comparison
Compare RMCO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- ALLR
- Stock Information
- Founded
- RMCO 2021
- ALLR 2004
- Country
- RMCO United States
- ALLR United States
- Employees
- RMCO N/A
- ALLR N/A
- Industry
- RMCO Multi-Sector Companies
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- ALLR Health Care
- Exchange
- RMCO Nasdaq
- ALLR Nasdaq
- Market Cap
- RMCO 14.9M
- ALLR 15.8M
- IPO Year
- RMCO N/A
- ALLR N/A
- Fundamental
- Price
- RMCO $2.02
- ALLR $1.73
- Analyst Decision
- RMCO
- ALLR Strong Buy
- Analyst Count
- RMCO 0
- ALLR 1
- Target Price
- RMCO N/A
- ALLR $9.00
- AVG Volume (30 Days)
- RMCO 106.9K
- ALLR 21.2M
- Earning Date
- RMCO 08-11-2025
- ALLR 08-15-2025
- Dividend Yield
- RMCO 0.25%
- ALLR N/A
- EPS Growth
- RMCO N/A
- ALLR N/A
- EPS
- RMCO N/A
- ALLR N/A
- Revenue
- RMCO $2,641,171.00
- ALLR N/A
- Revenue This Year
- RMCO N/A
- ALLR N/A
- Revenue Next Year
- RMCO N/A
- ALLR N/A
- P/E Ratio
- RMCO N/A
- ALLR N/A
- Revenue Growth
- RMCO 292.46
- ALLR N/A
- 52 Week Low
- RMCO $0.76
- ALLR $0.61
- 52 Week High
- RMCO $2.34
- ALLR $5.20
- Technical
- Relative Strength Index (RSI)
- RMCO 61.63
- ALLR 73.94
- Support Level
- RMCO $2.00
- ALLR $1.36
- Resistance Level
- RMCO $2.34
- ALLR $1.77
- Average True Range (ATR)
- RMCO 0.16
- ALLR 0.21
- MACD
- RMCO 0.03
- ALLR 0.08
- Stochastic Oscillator
- RMCO 59.49
- ALLR 58.94
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.